Dynavax Technologies Corporation
Dynavax is a commercial stage biopharmaceutical company committed to developing and commercializing novel vaccines to help protect the world against infectious diseases, by utilizing proven, innovative adjuvant technology. Our vision and work ethic are guided by the collective ideals underpinning Our Values, and these form the basis of our company culture.
We approach all that we do with integrity and quality to ensure we maintain trust and credibility with patients, colleagues, and all of our stakeholders.
We recognize each team member as an individual, respecting who they are, and the combined value of everyone’s unique perspectives and experiences.
We provide support and encouragement to each other, both personally and professionally, to create a community focused on working together to accomplish our shared goals.
We operate from a place of trust and high expectations inspiring one another to take ownership, venture beyond the obvious, and to bring our best every day.
Together, as one team focused on results, we confront challenges with confidence and enthusiasm never letting obstacles or hard work deter us from driving innovation.
Our management team is comprised of industry veterans that have extensive expertise in drug development and commercialization. With experience spanning successful biopharmaceutical companies to pertinent government organizations, they bring a rich knowledge-base to lead a growing fast-paced company.
Dynavax GmbH (Dynavax Europe), is the European affiliate of Dynavax Technologies Corporation. For more than 25 years, we have been dedicated to the development and manufacturing of vaccines and biopharmaceuticals.
Dynavax Europe is led by an experienced management team with demonstrated expertise in vaccine and biopharmaceutical product development and manufacturing.
Dynavax Europe (formerly known as Rhein Biotech) is using a state-of-the-art technology based on Hansenula polymorpha which has been continuously improved since the late Eighties. The Hansenula polymorpha technology is a basis for a number of global vaccines and biopharmaceuticals registered in over 90 countries world-wide and distributed over national and supra-national organizations (UNICEF, PAHO etc.) such as:
|HepavaxGene®||(3-dose Hepatitis B)||Johnson & Johnson|
|Quinvaxem®||(Pentavalent vaccine)||Johnson & Johnson|
|Gen Vax B®||(3-dose Hepatitis B)||Serum Institute of India|
|Biovac-B®||(3-dose Hepatitis B)||Wockhardt Ltd, India|
|Wosulin®||(Insulin)||Wockhardt Ltd, India|
|Phytase SP1002®||(Phytase)||DSM (Roche Vitamins)|
We have out-licensed these products to our partners, transferring the production technologies for implementation at their manufacturing facilities. In addition, we have supported the development and GMP manufacturing of several product candidates that are currently in clinical development or close to registration.
We have developed manufacturing processes for multiple subtypes of hepatitis B virus antigens for clinical and commercial use. For the diagnostic market, we have used our vaccine production technologies to manufacture and supply recombinant antigens.